For over 25 years, VMRD (formerly ABR) has served the global pharmaceutical and biotechnology industries with world-class adventitious agent testing services including virology, sterility, and mycoplasma testing services. The team of scientists at VMRD is dedicated to providing accurate, timely, and precise results, while ensuring a high degree of customer service. VMRD continues to design and develop virus detection protocols and other assays to meet evolving needs and changing regulations. VMRD's virus assays satisfy United States 9th Code of Federal Regulation (9CFR), European Medicines Agency (EMA/EMEA), CVMP and CHMP (CPMP) regulations. Additionally, VMRD operates under the principles of Good Laboratory Practice (GLP) as defined in the Twenty-first Code of Federal Regulations (21CFR), Part 58. In order to provide a wider service offering, VMRD has recently developed assays for mycoplasma by USDA-9CFR, European Pharmacopeia (EP), United States Pharmacopeia (USP) and the FDA requirements as well as species of origin and IgG level tests. More assays and other regulatory compliance methods are under development.